Cytek Biosciences Net Asset
| CTKB Stock | USD 4.48 0.08 1.82% |
As of the 2nd of March, Cytek Biosciences shows the Standard Deviation of 2.73, risk adjusted performance of (0.1), and Mean Deviation of 1.99. Cytek Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Cytek Biosciences Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.7132 | Revenue |
Cytek | Net Asset | Build AI portfolio with Cytek Stock |
Cytek Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Cytek Biosciences is extremely important. It helps to project a fair market value of Cytek Stock properly, considering its historical fundamentals such as Net Asset. Since Cytek Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cytek Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cytek Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. Projected growth potential of Cytek fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytek Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.735 | Earnings Share (0.11) | Revenue Per Share | Quarterly Revenue Growth 0.081 | Return On Assets |
Investors evaluate Cytek Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytek Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Cytek Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytek Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytek Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytek Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.
Cytek Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cytek Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cytek Biosciences.
| 12/02/2025 |
| 03/02/2026 |
If you would invest 0.00 in Cytek Biosciences on December 2, 2025 and sell it all today you would earn a total of 0.00 from holding Cytek Biosciences or generate 0.0% return on investment in Cytek Biosciences over 90 days. Cytek Biosciences is related to or competes with Varex Imaging, Avanos Medical, Standard Biotools, Clearpoint Neuro, Treace Medical, CeriBell, and Orthopediatrics Corp. Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific adv... More
Cytek Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cytek Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cytek Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 15.14 | |||
| Value At Risk | (4.53) | |||
| Potential Upside | 3.95 |
Cytek Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytek Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cytek Biosciences' standard deviation. In reality, there are many statistical measures that can use Cytek Biosciences historical prices to predict the future Cytek Biosciences' volatility.| Risk Adjusted Performance | (0.1) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | (0.67) | |||
| Treynor Ratio | (0.28) |
Cytek Biosciences March 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (0.27) | |||
| Mean Deviation | 1.99 | |||
| Coefficient Of Variation | (729.99) | |||
| Standard Deviation | 2.73 | |||
| Variance | 7.46 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | (0.67) | |||
| Treynor Ratio | (0.28) | |||
| Maximum Drawdown | 15.14 | |||
| Value At Risk | (4.53) | |||
| Potential Upside | 3.95 | |||
| Skewness | (0.05) | |||
| Kurtosis | 1.1 |
Cytek Biosciences Backtested Returns
Cytek Biosciences secures Sharpe Ratio (or Efficiency) of -0.0983, which signifies that the company had a -0.0983 % return per unit of risk over the last 3 months. Cytek Biosciences exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cytek Biosciences' Risk Adjusted Performance of (0.1), mean deviation of 1.99, and Standard Deviation of 2.73 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.36, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cytek Biosciences will likely underperform. At this point, Cytek Biosciences has a negative expected return of -0.27%. Please make sure to confirm Cytek Biosciences' accumulation distribution, and the relationship between the potential upside and day median price , to decide if Cytek Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.34 |
Poor reverse predictability
Cytek Biosciences has poor reverse predictability. Overlapping area represents the amount of predictability between Cytek Biosciences time series from 2nd of December 2025 to 16th of January 2026 and 16th of January 2026 to 2nd of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cytek Biosciences price movement. The serial correlation of -0.34 indicates that nearly 34.0% of current Cytek Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.34 | |
| Spearman Rank Test | -0.46 | |
| Residual Average | 0.0 | |
| Price Variance | 0.2 |
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Cytek Total Assets
Total Assets |
|
Based on the recorded statements, Cytek Biosciences has a Net Asset of 461.54 M. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Cytek Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytek Biosciences' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytek Biosciences could also be used in its relative valuation, which is a method of valuing Cytek Biosciences by comparing valuation metrics of similar companies.Cytek Biosciences is currently under evaluation in net asset category among its peers.
Cytek Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cytek Biosciences from analyzing Cytek Biosciences' financial statements. These drivers represent accounts that assess Cytek Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cytek Biosciences' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 2.2B | 1.4B | 1.2B | 645.1M | 741.9M | 704.8M | |
| Enterprise Value | 1.8B | 1.1B | 1.1B | 568.3M | 653.6M | 620.9M |
Cytek Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cytek Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cytek Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Cytek Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Cytek Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Cytek Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cytek Biosciences' value.| Shares | Morgan Stanley - Brokerage Accounts | 2025-09-30 | 1.5 M | Charles Schwab Investment Management Inc | 2025-12-31 | 1.1 M | Aqr Capital Management Llc | 2025-09-30 | 1 M | Northern Trust Corp | 2025-09-30 | 1 M | Wellington Management Company Llp | 2025-12-31 | 764.3 K | Jpmorgan Chase & Co | 2025-09-30 | 717.4 K | Renaissance Technologies Corp | 2025-12-31 | 675 K | Bank Of New York Mellon Corp | 2025-09-30 | 673.6 K | Principal Financial Group Inc | 2025-09-30 | 623.3 K | Blackrock Inc | 2025-09-30 | 16.5 M | Vanguard Group Inc | 2025-12-31 | 7.5 M |
Cytek Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0525 | ||||
| Profit Margin | (0.33) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 337.21 M | ||||
| Shares Outstanding | 127.86 M | ||||
| Shares Owned By Insiders | 9.37 % | ||||
| Shares Owned By Institutions | 65.09 % | ||||
| Number Of Shares Shorted | 6.71 M | ||||
| Price To Book | 1.52 X | ||||
| Price To Sales | 2.84 X | ||||
| Revenue | 201.49 M | ||||
| Gross Profit | 104.46 M | ||||
| EBITDA | (17.39 M) | ||||
| Net Income | (66.54 M) | ||||
| Cash And Equivalents | 349.89 M | ||||
| Cash Per Share | 2.60 X | ||||
| Total Debt | 14.04 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 10.47 X | ||||
| Book Value Per Share | 2.66 X | ||||
| Cash Flow From Operations | (4.69 M) | ||||
| Short Ratio | 7.59 X | ||||
| Earnings Per Share | (0.11) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 692 | ||||
| Beta | 1.3 | ||||
| Market Capitalization | 572.83 M | ||||
| Total Asset | 461.54 M | ||||
| Retained Earnings | (101.74 M) | ||||
| Working Capital | 328.78 M | ||||
| Net Asset | 461.54 M |
About Cytek Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytek Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytek Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytek Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:Check out For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. Projected growth potential of Cytek fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytek Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.735 | Earnings Share (0.11) | Revenue Per Share | Quarterly Revenue Growth 0.081 | Return On Assets |
Investors evaluate Cytek Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytek Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Cytek Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytek Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytek Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytek Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.